|
1
|
Orlando A, Mocciaro F, Renna S, Scimeca D,
Rispo A, Lia Scribano M, Testa A, Aratari A, Bossa F, Tambasco R,
et al: Early post-operative endoscopic recurrence in Crohn's
disease patients: data from an Italian Group for the study of
inflammatory bowel disease (IG-IBD) study on a large prospective
multicenter cohort. J Crohns Colitis. 8:1217–1221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pineton de Chambrun GP and Sandborn WJ:
IBD in 2011: Advances in IBD management-towards a tailored
approach. Nat Rev Gastroenterol Hepatol. 9:70–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martin TD, Chan SS and Hart AR:
environmental factors in the relapse and recurrence of inflammatory
bowel disease: A review of the literature. Dig Dis Sci.
60:1396–1405. 2015. View Article : Google Scholar
|
|
4
|
Spooren CE, Pierik MJ, Zeegers MP, Feskens
EJ, Masclee AA and Jonkers DM: Review article: The association of
diet with onset and relapse in patients with inflammatory bowel
disease. Aliment Pharmacol Ther. 38:1172–1187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schaffer T and Schoepfer AM: Serum
ficolin-2 correlates worse than fecal calprotectin and CRP with
endoscopic Crohn's disease activity. J Crohns Colitis. 8:1125–1132.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minar P, Haberman Y, Jurickova I, Wen T,
Rothenberg ME, Kim MO, Saeed SA, Baldassano RN, Stephens M,
Markowitz J, et al: Utility of neutrophil Fcγ receptor I (CD64)
index as a biomarker for mucosal inflammation in pediatric Crohn's
disease. Inflamm Bowel Dis. 20:1037–1048. 2014.PubMed/NCBI
|
|
7
|
Däbritz J, Bonkowski E, Chalk C, Trapnell
BC, Langhorst J, Denson LA and Foell D: Granulocyte macrophage
colony-stimulating factor auto-antibodies and disease relapse in
inflammatory bowel disease. Am J Gastroenterol. 108:1901–1910.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naismith GD, Smith LA, Barry SJ, Munro JI,
Laird S, Rankin K, Morris AJ, Winter JW and Gaya DR: A prospective
evaluation of the predictive value of faecal calprotectin in
quiescent Crohn's disease. J Crohns Colitis. 8:1022–1029. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Foell D, Wittkowski H and Roth J:
Monitoring disease activity by stool analyses: From occult blood to
molecular markers of intestinal inflammation and damage. Gut.
58:859–868. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Masclee GM, Penders J, Jonkers DM, Wolffs
PF and Pierik MJ: Is clostridium difficile associated with relapse
of inflammatory bowel disease? Results from a retrospective and
prospective cohort study in the Netherlands. Inflamm Bowel Dis.
19:2125–2131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sorrentino D, Nash P, Viladomiu M,
Hontecillas R and Bassaganya-Riera J: Stopping anti-TNF agents in
patients with Crohn's disease in remission: Is it a feasible
long-term strategy? Inflamm Bowel Dis. 20:7570–766. 2014.
|
|
12
|
Dai C, Liu WX, Jiang M and Sun MJ: Mucosal
healing did not predict sustained clinical remission in patients
with ibd after discontinuation of one-year infliximab therapy. PLoS
One. 9:e1107972014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kennedy NA, Kalla R, Warner B, Gambles CJ,
Musy R, Reynolds S, Dattani R, Nayee H, Felwick R, Harris R, et al:
Thiopurine withdrawal during sustained clinical remission in
inflammatory bowel disease: Relapse and recapture rates, with
predictive factors in 237 patients. Aliment Pharmacol Ther.
40:1313–1323. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Regueiro M, Kip KE, Baidoo L, Swoger JM
and Schraut W: Postoperative therapy with infliximab prevents
long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol.
12:1494–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farkas K, Lakatos PL, Nagy F, Szepes Z,
Miheller P, Papp M, Palatka K, Bálint A, Bor R, Wittmann T and
Molnár T: Predictors of relapse in patients with ulcerative colitis
in remission after one-year of infliximab therapy. Scand J
Gastroenterol. 48:1394–1398. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Keyashian K: Does endoscopic assessment of
mucosal healing affect IBD management? Dig Dis Sci. 59:2351–2353.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mańkowska-Wierzbicka D, Swora-Cwynar E,
Poniedziałek B, Adamski Z, Dobrowolska A and Karczewski J:
Usefulness of selected laboratory markers in ulcerative colitis.
Eur Cytokine Netw. Oct 13–2015.Epub ahead of print.
|
|
18
|
Monteleone G, Di Sabatino A, Ardizzone S,
Pallone F, Usiskin K, Zhan X, Rossiter G and Neurath MF: Impact of
patient characteristics on the clinical efficacy of mongersen
(GED-0301), an oral Smad7 antisense oligonucleotide, in active
Crohn's disease. Aliment Pharmacol Ther. Jan 13–2016.Epub ahead of
print. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Neurath MF: Cytokines in inflammatory
bowel disease. Nat Rev Immunol. 14:329–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hundorfean G, Neurath MF and Mudter J:
Functional relevance of T helper 17 (Th17) cells and the IL-17
cytokine family in inflammatory bowel disease. Inflamm Bowel Dis.
18:180–186. 2012. View Article : Google Scholar
|
|
22
|
Aine B, Grainne L and Kate K:
Transcriptional profiling of the colonic mucosa and epithelial
cells of patients with acutely active ulcerative colitis. Inflamm
Bowel Dis. (Suppl 1): S10–S11. 2014. View Article : Google Scholar
|
|
23
|
Yanai H, Ben-Shachar S, Baram L, Elad H,
Gitstein G, Brazowski E, Tulchinsky H, Pasmanik-Chor M and Dotan I:
Gene expression alterations in ulcerative colitis patients after
restorative proctocolectomy extend to the small bowel proximal to
the pouch. Gut. 64:756–764. 2015. View Article : Google Scholar
|
|
24
|
Abraham C and Medzhitov R: Interactions
between the host innate immune system and microbes in inflammatory
bowel disease. Gastroenterology. 140:1729–1737. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
MacDonald TT, Biancheri P, Sarra M and
Monteleone G: What's the next best cytokine target in IBD? Inflamm
Bowel Dis. 18:2180–2189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cader MZ and Kaser A: Recent advances in
inflammatory bowel disease: Mucosal immune cells in intestinal
inflammation. Gut. 62:1653–1664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Henderson P, van Limbergen JE, Schwarze J
and Wilson DC: Function of the intestinal epithelium and its
dysregulation in inflammatory bowel disease. Inflamm Bowel Dis.
17:382–395. 2011. View Article : Google Scholar
|
|
28
|
Nguyen GC, Patel H and Chong RY: Increased
prevalence of and associated mortality with methicillin-resistant
Staphylococcus aureus among hospitalized IBD patients. Am J
Gastroenterol. 105:371–377. 2010. View Article : Google Scholar
|
|
29
|
Bryant RV, Winer S, Travis SP and Riddell
RH: Systematic review: Histological remission in inflammatory bowel
disease. Is 'complete' remission the new treatment paradigm? An
IOIBD initiative. J Crohns Colitis. 8:1582–1597. 2014. View Article : Google Scholar : PubMed/NCBI
|
